“It has been nine months since the patient with beta thalassemia received the one-time-only treatment and over four months for the patient with sickle cell disease. In that time, both of their conditions have improved tremendously, Leiden says. The patient with beta thalassemia, who used to undergo more than 16 blood transfusions each year, hasn’t needed an infusion since the treatment. The patient with sickle cell disease experienced an average of seven excruciating health crises per year before the treatment, and since the treatment hasn’t experienced any.”
4 Likes
I read about this. I’m hoping early success will put the medical community at ease in developing it further cures for humans. Hoping for a cascade effect.
3 Likes